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A B S T R A C T
A series of novel tetrazole containing 1,2,3-thiadiazole derivatives were designed and synthesized via
Ugi reaction. Their structures were conﬁrmed by melting points, IR, 1H NMR, and HRMS (ESI).
Preliminary bioassay indicated that most target compounds exhibited very good direct anti-TMV activity
at 100 mg/mL, which was equal to or higher than that of ribavirin. Among them, compounds 4b, 4c and 4i
also showed equivalent protection effect to ribavirin in vivo at 100 mg/mL.
 2013 Zhi-Jin Fan. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Chinese Chemical Letters
jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/cc le t1. Introduction
1,2,3-Thiadiazoles and tetrazoles are important heterocyclic
compounds, both present a wide spectrum of biological
activities. 1,2,3-Thiadiazoles have antitumor [1], antiviral [2],
fungicidal [3,4], antibacterial [5] and insecticidal [6] activities.
Successful commercialization of some 1,2,3-thiadiazoles such as
tiadinil (TDL) [7] and acibenzolar-S-methyl (BTH) [8] as elicitors
accelerated the studies of their synthesis and systemic acquired
resistance (SAR). [9–11] Tetrazoles and their derivatives have
been reported as antibacterial [12], antiviral [13], herbicidal [14],
anti-inﬂammatory [15] antitumor [16], analgesic [17], and anti-
proliferative [18] agents. There are many reports about each of the
two heterocyclics, but the combination of 1,2,3-thiadiazole ring with
tetrazole ring in one molecule is seldom reported both in chemistry
and their biological activity studies.
Multicomponent reactions (MCRs), in which three or more
reactants in one pot generate products containing almost all atoms
of the reactant molecules, have been developed extensively as* Corresponding author.
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synthesis [19]. Among the MCRs, the Ugi four-component conden-
sation reaction (U-4CR) features many applications in organic
syntheses and medicinal chemistry [20,21]. The classical U-4CR
between amine, aldehyde, carboxylic acid and isocyanide affords
peptidic structures in high diversity. The Ugi-tetrazole synthesis is a
variation of the classical Ugi-reaction where azidotrimethylsilane
(TMSN3) is employed as an acid component [22] and this synthetic
strategy has been applied to the synthesis of various 1,5-
disubstituted tetrazoles [23,24]. To develop novel candidate
pesticides with diverse biological activities, tetrazole moiety was
introduced into 1,2,3-thiadizole, and a series of novel tetrazole
containing 1,2,3-thiadiazole derivatives were designed and synthe-
sized via U-4CR. Their antivirus activities against tobacco mosaic
virus (TMV) were also evaluated.
2. Experimental
Melting points of all compounds were determined on an X-4
binocular microscope (Gongyi Technical Instrument Co., Henan,
China), and the thermometer was not corrected. Proton NMR
spectra were obtained using a Bruker AVANCE-400 MHz spec-
trometer, and chemical shift values (d) were reported as parts per
million (ppm) with deuteron chloroform (CDCl3) as the solvent
and tetramethylsilane (TMS) as the internal standard. Highlf of Chinese Chemical Society. All rights reserved.
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Scheme 1. General synthetic route of the target compounds 4a–4m. Reagents and conditions: (a) NaBH4 (2.0 equiv.), EtOH, 0 8C for 1 h, r.t. for 6 h; (b) pyridinium
chlorochromate (2.0 equiv.), CH2Cl2, r.t. for 8 h; (c) (i) R-NH2 (1.0 equiv.), CH3OH, r.t. for 0.5–1 h; (ii) cyclohexyl isocyanide (1.2 equiv.), TMSN3 (1.5 equiv.), r.t. for 12–24 h.
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FTICR-MS Varian 7.0T FTICR-MS instrument. All the reagents
were obtained commercially and used after further puriﬁcation.
Column chromatography puriﬁcation was carried out by using
silica gel.
General procedure for synthesis of compounds 4a–4m
(Scheme 1): 4-Methyl-1,2,3-thiadiazole-5-carbaldehyde 3
(0.21 g, 1.6 mmol) and substituted amine (1.6 mmol) were stirred
in 8 mL methanol at room temperature. The imine was pre-
condensated for 0.5–1 h and then cyclohexyl isocyanide (0.21 g,
1.9 mmol) and TMSN3 (0.28 g, 2.4 mmol) were added. The
reaction mixture was stirred for 12–24 h at room temperature
until the reaction was completed (indicated by TLC). Then the
organic solvent was evaporated in vacuo. The crude products were
puriﬁed by a silica gel column using ethyl acetate/petroleum ether
(1:2–1:3 (v/v), 60–90 8C) as an eluent to give 4a–4m as white or
pale yellow solids in moderate yields.
Direct anti-TMV activity of target compounds 4a–4m was
conducted by half leaf juice robbing methods according to Ref.
[25]. Protection effect against TMV in vivo was evaluated on N.
tabacum L. leaves [4]. Healthy fresh tobacco plants at the six-leaf
stage were selected for the tests. The compound solution was
smeared on the whole leaves, and then the leaves were dried in the
greenhouse. After 12 h, TMV at a concentration of 5.88  102 mg/
mL was inoculated on the upper three leaves using the
conventional juice robbing method, and the solvent was smeared
on the lower three leaves as a control. The local lesion numbers
were then recorded 2–3 days after inoculation. For each
compound, three repetitions were conducted. All compounds
were tested at concentrations of 100 mg/mL. Ribavirin and
ningnanmycin were used as positive control at the same time.
The activity data of protection effect against TMV was calculated
by the following equation:
Y ¼ CK  A
CK
 100%
where Y is the antivirus inhibition ratio (%), CK is the average
number of viral inﬂammations on the control leaves in vivo, and A
is the average number of viral inﬂammations on the target
compound treated leaves in vivo.Table 1
Direct antivirus activity and protection effect in vivo against TMV of target compounds
Compd. Anti-TMV (%) Protection (%) Compd. Anti-TMV (%) 
4a 29.58 12.60 4f 22.14 
4b 36.49 36.59 4g 29.72 
4c 33.75 37.81 4h 33.23 
4d 32.17 30.90 4i 40.04 
4e 44.25 9.76 4j 23.01 3. Results and discussion
The synthesis route of the target compounds was outlined in
Scheme 1. The starting material, ethyl 4-methyl-1,2,3-thiadiazole-
5-carboxylate 1, was prepared according to Ref. [9]. Cyclohexyl
isocyanide was synthesized according to Ref. [4]. The intermediate
(4-methyl-1,2,3-thiadiazol-5-yl)methanol 2 was obtained in high
yields by reduction of 1 with NaBH4 at 0 8C to room temperature.
Treatment of a intermediate 2 with pyridinium chlorochromate at
room temperature produced 4-methyl-1,2,3-thiadiazole-5-carbal-
dehyde 3 in 86% yields. The target compounds 4a–4m were
obtained by the U-4CR of 3 with substituted amines, cyclohexyl
isocyanide and TMSN3 in methanol in moderate yields, which were
white or pale yellow solid after column chromatography puriﬁca-
tion.
The structures of the target compounds synthesized herein
were fully characterized by melting points, 1H NMR, IR, and HRMS
(ESI) [26]. In the IR spectra of compounds 4a–4m, strong
absorptions at about 3300 cm1 were detected, due to the
secondary amino group. In the 1H NMR spectra, CH3 of 1,2,3-
thiadizole were observed at d 2.57–2.66. Furthermore, a doublet
signal at about d 4.80 due to the NH proton coupled with the
aromatic proton at about d 7.00 as seen for compounds 4i–4m; as
for compounds 4a–4h, the NH proton doublet was not always
clearly detected because of overlapping with the aliphatic protons.
The HRMS (ESI) spectral data of all compounds are in good
agreement with theoretical data.
The results of direct anti-TMV activity and protection effect of
all target compounds were listed in Table 1. As shown in the data,
most compounds have very good anti-TMV activity at 100 mg/mL,
which were equal to or higher than that of the positive control
ribavirin. Among them, compound 4l showed excellent anti-TMV
activity with inhibition activity of 48.73%, which was higher than
that of ninamycin. Besides possessing good direct anti-TMV
activity, compounds 4b, 4c and 4i also presented very good
protection effect in vivo at 100 mg/mL, which were equivalent to
the positive control ribavirin. After a structural comparison, it was
very clear that the whole molecular structure played an important
role in anti-TMV activity rather than one moiety in the molecule.
Our results indicate that the combination of 1,2,3-thiadiazole ring at 100 mg/mL.
Protection (%) Compd. Anti-TMV (%) Protection (%)
12.60 4k 37.60 12.41
6.91 4l 48.73 4.47
21.14 4m 41.57 22.36
39.02 Ribavirin 33.23 36.52
8.95 Ninamycin 47.63 40.43
S.-X. Wang et al. / Chinese Chemical Letters 24 (2013) 889–892 891with tetrazole ring in one molecule can improve their biological
activities. This provides us with useful clues for further research of
ﬁnding novel leading structures possessing good antivirus activity
based on the structure reported in this paper.
4. Conclusion
In summary, a series of novel tetrazole containing 1,2,3-
thiadiazole derivatives were synthesized via a simpliﬁed Ugi-
tetrazole reaction and easily puriﬁed. The bioassay tests indicated
that most target compounds have higher anti-TMV activity than
that of ribavirin did at 100 mg/mL. Compounds 4b, 4c and 4i also
showed equivalent protection effect to ribavirin in vivo at 100 mg/
mL. These studies indicate that the newly synthesized tetrazole
containing 1,2,3-thiadiazole derivatives possessed good potential
bioactivities, and were worthy of further study in pesticide
development.
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1H, CH). HRMS: Calcd. for
C15H25N7S (M+Na)
+: 358.1784, Found: 358.1787; IR (KBr pellet press, cm-1):
v3327, 2938, 2865, 1453, 1231, 1103, 1076, 861, 741. 4f: White solid; yield
60%; mp 87–88 8C; 1H NMR (400 MHz, CDCl3):d 1.26–2.17 (m, 17H, 6 cyclobutyl-
H, 10 cyclohexyl-H, NH), 2.63 (s, 3H, thiadiazole-CH3), 3.11–3.14 (m, 1H, cyclo-
butyl-CH), 4.49–4.56 (m, 1H, cyclohexyl-CH), 5.70 (s, 1H, CH). HRMS: Calcd. for
C15H23N7S (M+Na)
+: 356.1628, Found: 356.1629; IR (KBr pellet press, cm1):
v3264, 2941, 2856, 1501, 1451, 1241, 1150, 1105, 1009, 809, 759. 4g: White solid;
yield 58%; mp 122-123 8C; 1H NMR (400 MHz, CDCl3):d 1.32–2.00 (m, 19H, 8
cyclopentyl-H, 10 cyclohexyl-H, NH), 2.63 (s, 3H, thiadiazole-CH3), 2.89–2.95 (m,
1H, cyclopentyl-CH), 4.53–4.60 (m, 1H, cyclohexyl-CH), 5.72 (s, 1H, CH). HRMS:
Calcd. for C16H25N7S (MH): 346.1819, Found: 346.1814; IR (KBr pellet press,
cm1): v3271, 2938, 2857, 1499, 1449, 1236, 1087, 1005, 844, 732. 4h: White
solid; yield 47%; mp 98–99 8C; 1H NMR (400 MHz, CDCl3):d 1.11–2.05 (m, 21H, 20
cyclohexyl-H, NH), 2.30–2.32 (m, 1H, cyclohexyl-CH), 2.62 (s, 3H, thiadiazole-
CH3), 4.56–4.64 (m, 1H, cyclohexyl-H), 5.90 (s, 1H, CH). HRMS: Calcd. for
C17H27N7S (MH): 360.1976, Found: 360.1973; IR (KBr pellet press, cm1):
v3286, 2927, 2850, 1451, 1236, 1106, 1012, 824, 686. 4i: White solid; yield 55%;
mp 96–97 8C; 1H NMR (400 MHz, CDCl3):d 1.26–1.99 (m, 10H, cyclohexyl-H), 2.65
(s, 3H, thiadiazole-CH3), 4.35–4.41 (m, 1H, cyclohexyl-H), 4.72 (d, 1H, J = 8.0 Hz,
NH), 6.32 (d, 1H, J = 8.0 Hz, CH), 6.66–7.09 (m, 4H, Ph-H). HRMS: Calcd. for
C17H20FN7S (M+H)
+: 374.1558, Found: 374.1555; IR (KBr pellet press, cm1):
v3401, 2936, 2860, 1620, 1527, 1453, 1251, 1191, 1057, 738. 4j: Pale yellow solid;
yield 50%; mp 115–116 8C; 1H NMR (400 MHz, CDCl3):d 1.26–1.99 (m, 10H, 10
cyclohexyl-H), 2.66 (s, 3H, thiadiazole-CH3), 4.27–4.33 (m, 1H, cyclohexyl-CH),
5.09 (d, 1H, J = 6.0 Hz, NH), 6.23 (d, 1H, J = 7.6 Hz, CH), 6.56 (d, 1H, J = 8.4 Hz, Ph-
H), 6.70 (s, 1H, Ph-H), 6.85 (d, 1H, J = 8.4 Hz, Ph-H), 7.12 (t, 1H, J = 8.0 Hz, Ph-H).
HRMS: Calcd. for C17H20ClN7S (MH): 388.1117, Found: 388.1112; IR (KBr pellet
press, cm1): v3410, 2937, 2861, 1598, 1484, 1446, 1272, 1158, 1012, 845, 759.
4k: Pale yellow solid; yield 46%; mp 152–153 8C; 1H NMR (400 MHz, CDCl3):d
1.26–2.01 (m, 10H, 10 cyclohexyl-H), 2.66 (s, 3H, thiadiazole-CH3), 4.25–4.32 (m,
S.-X. Wang et al. / Chinese Chemical Letters 24 (2013) 889–8928921H, cyclohexyl-CH), 4.80 (d, 1H, J = 7.2 Hz, NH), 6.20 (d, 1H, J = 7.2 Hz, CH), 6.63 (d,
2H, J = 8.8 Hz, Ph-H), 7.18 (d, 2H, J = 8.4 Hz, Ph-H). HRMS: Calcd. for C17H20ClN7S
(MH): 388.1117, Found: 388.1119; IR (KBr pellet press, cm1): v3285, 2944,
2856, 1598, 1497, 1442, 1296, 1245, 1103, 1011, 837. 4l: White solid; yield 45%;
mp 149–150 (oC; 1H NMR (400 MHz, CDCl3):d 1.17 (t, 3H, J = 7.6 Hz, ethyl-CH3),
1.24-2.00 (m, 10H, 10 cyclohexyl-H), 2.50 (q, 2H, J = 15.2 Hz, ethyl-CH2), 2.63 (s,
3H, thiadiazole-CH3), 4.27-4.34 (m, 1H, cyclohexyl-CH), 4.41 (d, 1H, J = 5.2 Hz,
NH), 6.18 (d, 1H, J = 8.0 Hz, CH), 6.63 (d, 2H, J = 8.4 Hz, Ph-H), 7.05 (d, 2H,,J = 8.4 Hz, Ph-H). HRMS: Calcd. for C19H25N7S (M+Na)
+: 406.1784, Found:
406.1783; IR (KBr pellet press, cm1): v3419, 2935, 2862, 1616, 1523, 1446,
1281, 1102, 818, 756. 4m: White solid; yield 48%; mp 143–144 (C; 1H NMR
(400 MHz, CDCl3): d 1.27-2.00 (m, 10H, cyclohexyl-H), 2.15 (s, 3H, Ph-CH3), 2.65
(s, 3H, thiadiazole-CH3), 4.29-4.34 (m, 1H, cyclohexyl-CH), 4.75 (d, 1H, J = 7.6 Hz,
NH), 6.19 (d, 1H, J = 7.6 Hz, CH), 6.36-6.41 (m, 2H, PhH), 7.00 (t, 1H, J = 8.4 Hz,
PhH). HRMS: Calcd. for C18H22FN7S (MH): 386.1569, Found: 386.1571; IR (KBr
pellet press, cm1): v3285, 2927, 2849, 1496, 1450, 1236, 1133, 1012, 824, 686.
